Although an unplanned, interim analysis from an ongoing randomized trial in Sweden has suggested no significant difference in mortality between patients with peripheral artery disease receiving paclitaxel-coated devices and those receiving uncoated devices for lower-extremity revascularization, the analysis did not resolve the question of whether paclitaxel-coated devices are safe for these patients.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Mortality is not associated with paclitaxel-coated devices usage in peripheral arterial disease of lower extremities
Scientific Reports Open Access 14 September 2021
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Schramm, K. M. et al. Recent trends in clinical setting and provider specialty for endovascular peripheral artery disease interventions for the Medicare population. J. Vasc. Interv. Radiol. 31, 614–621 (2020).
Lindquist, J. & Shramm, K. Drug-eluting balloons and drug-eluting stents in the treatment of peripheral vascular disease. Semin. Intervent. Radiol. 35, 443–452 (2018).
Ng, V. G., Mena, C., Pietras, C. & Lansky, A. J. Local delivery of paclitaxel in the treatment of peripheral artery disease. Eur. J. Clin. Invest. 45, 333–345 (2015).
Rosenfield, K. et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N. Engl. J. Med. 373, 145–153 (2015).
Dake, M. D. et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation 133, 1472–1483 (2016).
Katsanos, K., Spiliopoulos, S., Kitrou, P., Krokidis, M. & Karnabatidis, D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J. Am. Heart Assoc. 7, e011245 (2018).
Dan, K. et al. Paclitaxel-related balloons and stents for the treatment of peripheral artery disease: insights from the Food and Drug Administration 2019 Circulatory System Devices Panel meeting on late mortality. Am. Heart J. 222, 112–120 (2020).
Nordanstig, J. et al. Mortality with paclitaxel-coated devices in peripheral artery disease. N. Engl. J. Med. 383, 2538–2546 (2020).
Stone, G. W. et al. Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS clinical trial program. JACC Cardiovasc. Interv. 4, 530–542 (2011).
Wang, J., Lou, P., Lesniewski, R. & Henkin, J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14, 13–19 (2003).
M.M.M. has received research funding from Regeneron and other research support from ArtAssist, Chromadex, Helixmith, Mars and ReserveAge. M.R.K. declares no competing interests.
About this article
Cite this article
McDermott, M.M., Kibbe, M.R. Safety of paclitaxel-coated devices in peripheral artery disease. Nat Rev Cardiol 18, 311–312 (2021). https://doi.org/10.1038/s41569-021-00531-6